UB

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%
HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$1.13B
EPS-0.7400
P/E Ratio-3.69
Earnings Date11/06/2025

upb

Operating Expenses

Last Annual Value

80.13M

3-Year CAGR

47%

5-Year CAGR

26%

10-Year CAGR

12%

UB

Upstream Bio, Inc. Competitors Analysis of Operating Expenses

UPB · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
80.13M
23.5%N/AN/A 
179.97M
52.2%65.3%34.5%
326.06M
97.9%14.3%N/A
205.66M
0.1%19.5%N/A
314.54M
-7.6%-3.1%N/A
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
126.75M
N/AN/AN/A
221.38M
36.4%N/AN/A
155.60M
57.4%N/AN/A
186.00M
-0.9%-18.7%-2.8%
312.50M
23.0%18.4%N/A
UB

Upstream Bio, Inc. Fair Value Envelope

UPB · NASDAQ

Our analysis suggests that UPB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.97, this represents a potential HIDDEN relative to our calculated worth for Upstream Bio, Inc..

Intrinsic Value
Current Price: $20.97